Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression ...Middle East

OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with...

Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression )

Also on site :

• At Least 11 Dead After Driver Plowed Into Crowd at a Filipino Festival in Vancouver
• What to know about the trial of an ex-Michigan cop charged in the killing of a Black motorist
• U.S. Military Says Its Air Campaign Has Hit More Than 800 Targets in Yemen